Post-ASH 2023 Multiple Myeloma Highlights

Featuring presentations & discussions on selected multiple myeloma abstracts
from the 65^th ASH Annual Meeting

31 Jan 2024 | 10am-1pm CST / 4-7pm GMT / 5-8pm CET

Please note that this webinar has passed – the recordings will be available on VJHemOnc soon

Chair: María-Victoria Mateos | Moderators: Faith Davies, Rafael Fonseca, Irene Ghobrial, Katja Weisel

*Please note: This webinar is for HCPs and allied health professionals only.
Your application to attend will be reviewed and confirmed by VJHemOnc.

Draft Agenda

10:00-10:45am CST

Session 1: Precursor

1. Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma; (206) Omar Nadeem
2. Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Myeloma Treated in the GEM-CESAR Trial; (645) Noemi Puig
3. Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma; (757) Benjamin Diamond
4. Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma (877) Malin Hultcrantz

Live Q&A

10:45-11:25am

Session 2: Approved CARs

4. The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Cilta-Cel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B); (1021) Jens Hillengass
5. Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Cilta-Cel Vs Standard of Care in Patients with Lenalidomide-Refractory Myeloma after 1-3 Lines of Therapy; (1063) Roberto Mina
6. Outcomes after CAR T Cells in Myeloma Patients with Extramedullary and Paramedullary Disease; (1006) Darren Pan
7. A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Myeloma Patients Treated with Ide-Cel; (1004) Doris Hansen

Live Q&A

11:25am-12:10pm

Session 3: Novel Agents

8. BMS-986393 (CC-95266), a GPRC5D- Targeted CAR T-Cell Therapy for R/R Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study; (219) Susan Bal
9. Phase 1 Study of CART-Ddbcma for the Treatment of Patients with R/R Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients; (1023) Matthew Frigault
10. ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care BCMA-Directed CAR T-Cell: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with R/R Myeloma; (1026) Aina Oliver-Caldés
11. Phase 2 EMN26: Iberdomide Maintenance after ASCT in Newly Diagnosed MM; (208) Niels van de Donk
12. Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC) Targeting BCMA for R/R Myeloma; (1012) Sumit Madan

Live Q&A

12:10-12:45pm

Session 4: Combinations

13. KRd Vs Rd in Newly Diagnosed Fit or Intermediate-Fit Myeloma Patients Not Eligible for ASCT (Phase III EMN20 Trial): Analysis of Sustained Undetectable MRD; (205) Benedetto Bruno
14. GEM2017FIT Trial: Induction Therapy with VMP Followed By Rd Vs KRd Plus/Minus Dara, 18 Cycles, Followed By Consolidation and Maintenance with R and Dara: Phase III, Multicenter, Randomized Trial for Elderly Fit NDMM Patients Aged between 65 and 80 Years; (209) María-Victoria Mateos
15. Talquetamab + Pomalidomide in Patients with R/R Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study; (1014) Jeffrey Matous

Live Q&A

12:45-1:15pm

Session 5: Assessment and stratification techniques

16. Minimally Invasive Assessment of MRD in Multiple Myeloma; (339) Carmen Gonzalez
17. Towards a Decision Engine for Therapeutic Optimization of R/R Multiple Myeloma; (341) Yael Cohen

Live Q&A

1:15pm CST | End of webinar

The Post-ASH 2023 Multiple Myeloma Highlights has been supported by: